L-carnitine treatment significantly enhanced the expression of CPT1A in Hg and FFA-treated mouse cardiac microvascular ECs, promoted the interaction between its downstream PHB2 and PARL, and then enhanced PINK1/Parkin-dependent mitophagy, inhibited the release of Cyt-C and the activation of Caspase-3, and improved mitochondrial dysfunction and cardiac microvascular damage in DCM (Li S. et al., 2023). The gene discussed is CPT1A; the disease is familial dilated cardiomyopathy.